Brief: Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors
26/03/2025 13:28
March 26 (Reuters) - Exelixis Inc EXEL.O: EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NEUROENDOCRINE TUMORS Source text: ID:nBw3NThYxa Further company coverage: EXEL.O ((Reuters.Briefs@thomsonreuters.com;))